Suppr超能文献

美国伴或不伴糖尿病的心力衰竭成年人的医疗保健支出。

Health Care Expenditure in United States Adults With Heart Failure With and Without Diabetes.

机构信息

Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, Maryland.

Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan UCLA Medical Center, Los Angeles, California.

出版信息

Am J Cardiol. 2024 Oct 1;228:10-15. doi: 10.1016/j.amjcard.2024.07.027. Epub 2024 Jul 25.

Abstract

The health costs for heart failure (HF) in patients with and without diabetes can help us understand the conjoint burden of diabetes and HF. Using the 2008 to 2019 US national Medical Expenditure Panel Survey data including 2,019 adults with HF and a 2-part adjusted model, we estimated the mean and adjusted incremental direct medical expenditures related to diabetes. The total direct expenditures for patients with HF increased by 27 %: $24,725 (95 % confidence interval [CI] $20,457 to $28,993) in 2008 to 2009 to $31,426 (95 % CI $25,705 to $37,147) in 2018 to 2019. The expenditures increased by 34 % in those with diabetes. Inpatient costs represented the highest fraction of costs ∼43.3 % and were 8 % higher in those with diabetes versus those without diabetes. The drug costs accounted for 24 % of all costs, increased by 44 %, and were 86 % higher in patients with HF with diabetes versus those without diabetes. The adjusted excess costs in patients with HF and diabetes versus HF without diabetes was $6,818 (95 % CI 2,241 to 11,395); the corresponding excess costs for drugs and medical costs other than drugs were $3,297 (95 % CI 2,168 to 4,426) and $3,554 (95 % CI -777 to 7,886). In US adults with HF, the estimated adjusted total direct excess costs were $5.2 billion per year higher in patients with diabetes versus those without diabetes. In conclusion, diabetes is associated with substantially increased health care costs in patients with HF, suggesting the need for an integrated management of diabetes and HF.

摘要

心力衰竭(HF)患者合并或不合并糖尿病的健康成本有助于我们了解糖尿病和 HF 的共同负担。利用 2008 年至 2019 年美国全国医疗支出调查数据,纳入 2019 例 HF 成人患者和 2 部分调整模型,我们估计了与糖尿病相关的直接医疗支出的平均值和调整后增量。HF 患者的总直接支出增加了 27%:2008 年至 2009 年为 24725 美元(95%可信区间[CI]为 20457 美元至 28993 美元),2018 年至 2019 年增至 31426 美元(95%CI 为 25705 美元至 37147 美元)。糖尿病患者的支出增加了 34%。住院费用占总费用的比例最高,约为 43.3%,糖尿病患者比非糖尿病患者高 8%。药物费用占所有费用的 24%,增加了 44%,糖尿病合并 HF 患者比非糖尿病患者高 86%。HF 合并糖尿病患者与 HF 不合并糖尿病患者相比,调整后超额费用为 6818 美元(95%CI 为 2241 美元至 11395 美元);药物和除药物以外的医疗费用的相应超额费用分别为 3297 美元(95%CI 为 2168 美元至 4426 美元)和 3554 美元(95%CI 为-777 美元至 7886 美元)。在美国 HF 成人患者中,与不合并糖尿病患者相比,合并糖尿病患者每年的估计调整后直接总超额费用高出 52 亿美元。总之,糖尿病与 HF 患者的医疗费用显著增加有关,这表明需要对糖尿病和 HF 进行综合管理。

相似文献

4
Economic costs of diabetes in the US in 2002.2002年美国糖尿病的经济成本。
Diabetes Care. 2003 Mar;26(3):917-32. doi: 10.2337/diacare.26.3.917.
9
Economic Costs of Diabetes in the U.S. in 2017.2017 年美国糖尿病的经济成本。
Diabetes Care. 2018 May;41(5):917-928. doi: 10.2337/dci18-0007. Epub 2018 Mar 22.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验